6L8 Stock Chart & Stats
€41.20
€4.40(16.67%)
At close: 4:00 PM EDT
€41.20
€4.40(16.67%)
Day’s Range― - ―
52-Week Range€10.80 - €48.40
Previous CloseN/A
Volume100.00
Average Volume (3M)18.00
Market Cap
€3.32B
Enterprise Value€1.82B
Total Cash (Recent Filing)€101.62M
Total Debt (Recent Filing)€6.77M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Nov 16, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding72,702,530
10 Day Avg. Volume9
30 Day Avg. Volume18
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)11.47
Price to Sales (P/S)2643.82
P/FCF Ratio-17.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€55.53Price Target Upside34.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.06
Revenue Forecast (FY)€1.81M
Bulls Say, Bears Say
Bulls Say
Clinical EvidenceStrong feasibility outcomes support the nsPFA platform’s clinical differentiation and may improve physician confidence as pivotal evidence develops. High freedom from AF alongside a low serious adverse event rate could strengthen adoption prospects if the results are replicated in larger studies.
Pivotal Trial ExecutionCompleting pivotal enrollment ahead of schedule demonstrates physician interest and operational execution across a multicenter study. It advances the company toward definitive safety and efficacy data, an important foundation for regulatory review and future commercialization.
Strategic Commercial PartnershipThe partnership provides both a commercial treatment site and a structured avenue for generating additional clinical evidence in benign thyroid nodules. Real-world outcomes from a specialized center could support market development and broader adoption if results remain favorable.
Bears Say
Limited Commercial RevenueThe very small revenue base shows that Pulse remains in an early commercialization stage, while negative gross profit indicates current sales do not yet support the cost structure. Scaling clinical programs without meaningful recurring product revenue keeps profitability distant and execution risk high.
Persistent Cash BurnLarge operating and free-cash-flow deficits mean development spending is translating into substantial cash outflows rather than internally funded growth. Continued burn can limit flexibility and requires successful financing or future commercialization to sustain the clinical and regulatory pipeline.
Financing Dependence And DilutionReliance on repeated equity financing supports near-term liquidity but can dilute existing holders and leaves the development plan exposed to future capital needs. With losses widening and clinical investment continuing, external funding remains an important part of the operating model.
Pulse Biosciences News
6L8 FAQ
What was Pulse Biosciences’s price range in the past 12 months?
Pulse Biosciences lowest stock price was €10.80 and its highest was €48.40 in the past 12 months.
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is €3.32B.
When is Pulse Biosciences’s upcoming earnings report date?
Pulse Biosciences’s upcoming earnings report date is Nov 16, 2026 which is in 25 days.
How were Pulse Biosciences’s earnings last quarter?
Pulse Biosciences released its earnings results on Aug 06, 2026. The company reported -€0.253 earnings per share for the quarter, beating the consensus estimate of -€0.276 by €0.023.
Is Pulse Biosciences overvalued?
According to Wall Street analysts Pulse Biosciences’s price is currently Undervalued.
Does Pulse Biosciences pay dividends?
Pulse Biosciences does not currently pay dividends.
What is Pulse Biosciences’s EPS estimate?
Pulse Biosciences’s EPS estimate is -0.28.
How many shares outstanding does Pulse Biosciences have?
Pulse Biosciences has 72,702,530 shares outstanding.
What happened to Pulse Biosciences’s price movement after its last earnings report?
Pulse Biosciences reported an EPS of -€0.253 in its last earnings report, beating expectations of -€0.276. Following the earnings report the stock price went down -1.227%.
Which hedge fund is a major shareholder of Pulse Biosciences?
Currently, no hedge funds are holding shares in DE:6L8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulse Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€55.53 (34.77% Upside)
€55.53 (34.77% Upside)
Blogger Sentiment
Bullish
DE:6L8 Sentiment 86%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth €178.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
179.18%
12-Months-Change
Fundamentals
Return on Equity
-94.42%
Trailing 12-Months
Asset Growth
-3.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pulse Biosciences
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
6L8 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, positive clinical momentum and operational progress: accelerated pivotal enrollment, compelling EU feasibility efficacy and safety data, procedural efficiency that suggests meaningful hospital economics, strengthened leadership, and a materially improved cash position following ATM proceeds. These positives are balanced by early-stage commercial revenue that remains small, rising operating expenses and widening losses driven by increased clinical investment, ongoing cash burn, and continued dependence on capital markets. Regulatory timing still depends on 12-month follow-up for earlier enrollees, creating a measurable timeline risk. On balance, the highlights — particularly the rapid enrollment, robust feasibility outcomes, and strengthened balance sheet — outweigh the lowlights.View all DE:6L8 earnings summaries6L8 Stock 12 Month Forecast
Average Price Target
€55.53
▲(34.77% Upside)